DNA double helix showing the relationship between methylation, NAD+, and NR

What Is Methylation? Exploring the Connection Between NAD+, NR, and Methyl Donor Balance

Key Takeaways

  • Methylation is essential for cellular health: It regulates gene expression, energy metabolism, detoxification, and overall cellular function.
  • Balance is key: Too few or too many methyl donors—affected by diet, genetics (like MTHFR mutations), and lifestyle—can disrupt methylation and long-term health.
  • NAD+ metabolism and aging: According to recent research, NAD+ biosynthesis through the NR pathway remains stable with age, making it a promising target for interventions such as NR supplementation.
  • B3 vitamins and methylation: Research shows that while all B3 vitamins contribute to NAD+ metabolism, NR does so without affecting methylation or depleting methyl donors, even at high doses, unlike niacin or nicotinamide.
  • TMG supplementation: While some practitioners may recommend co-supplementing TMG with NR in certain cases, there is no clinical evidence to suggest that NR supplementation alone disrupts methylation, even in individuals with MTHFR mutations.

As interest in metabolic health and longevity continues to grow, concepts once only seen in biochemistry textbooks—like methylation and nicotinamide adenine dinucleotide (NAD+) metabolism—have entered mainstream wellness conversations. Both concepts are fundamental to how our cells regulate energy production, gene expression, and cellular repair, and both play important roles in metabolic health¹ and liver function.²

Methylation refers broadly to the transfer of methyl groups within the body,³ a process that helps regulate DNA expression, detoxification, and cellular signaling. While methylation itself is not inherently “good” nor “bad,” health depends on maintaining the right balance. Disruptions to methylation balance—which could be from genetics,⁴ nutrient deficiencies,⁵ or environmental stressors⁴—can contribute to physiological dysfunction over time.

However, growing interest in NAD-boosting supplements like nicotinamide riboside (NR) has raised questions about whether supporting NAD+ levels could inadvertently interfere with methylation pathways. Much of this concern stems from older research on other forms of vitamin B3,⁶ which suggested potential methyl group depletion or a need for additional methyl donor supplementation, such as trimethylglycine (TMG).

In this article, we’ll take an evidence-based look at how methylation actually works—including the role of methyl donors, epigenetic regulation, and genetic factors such as the methylenetetrahydrofolate reductase (MTHFR) gene—and how NAD+ metabolism intersects with these systems. We’ll also clarify why NR differs from other B3 vitamins, and why current human data show that NR supports NAD+ without disrupting methylation balance, despite persistent misconceptions. 

What Is Methylation? How It Works and Why Balance Matters

Methylation is a fundamental biological process in which a small chemical group—a methyl group (CH3), made of one carbon atom and three hydrogen atoms—is added to molecules like DNA, proteins, or other compounds.³ 

In simple terms, a methylated molecule is any molecule that has had a methyl group attached. This small addition can change the molecule’s function—for example, turning a gene on or off, activating an enzyme, or altering a neurotransmitter.⁷

Conversely, a methyl donor is the source of that methyl group.⁸ This nutrient or compound “donates” a methyl group so that the methylation reaction can occur. Key nutrients that serve as methyl donors include folate (vitamin B9), methionine, choline, and betaine, which are found in foods like leafy greens, legumes, whole grains, eggs, fish, and certain meats.⁸ In most people who are eating a balanced diet, these nutrients are sufficient to support healthy methylation.

Methylation plays a critical role in nearly every cellular function. It acts as a master control system, regulating gene expression, maintaining DNA integrity, supporting protein function, driving energy metabolism, and preserving overall cellular health.⁹

However, methylation requires a careful balance. Insufficient methyl donors—due to genetic variations (such as mutations in the MTHFR gene,¹⁰ which can reduce folate metabolism), certain illnesses (like autoimmune disorders,¹¹ liver disease,¹² or infections¹³), chronic inflammation,¹⁴ or inadequate nutrient intake⁸—may slow or reduce methylation efficiency and contribute to physiological dysfunction over time. While outright nutrient deficiencies are uncommon in people with nutrient-rich diets, they can still occur in restrictive eating patterns or digestive disorders.

Conversely, excessive methyl donor availability—such as from over-supplementation—can also be problematic,¹⁵ potentially leading to imbalances in methylation reactions and unintended downstream consequences. This is why equilibrium is essential, as the body thrives when methylation pathways have adequate, but not excessive, resources.

Fortunately, humans are equipped with metabolic redundancy—meaning we have overlapping pathways that help preserve methylation balance even when methyl donor intake fluctuates.¹⁶ This metabolic flexibility allows cells to maintain stable methyl donor levels and ensure methylation-dependent processes continue uninterrupted.

Overall, proper methylation balance is essential for long-term health, supporting gene regulation, cellular function, efficient detoxification, energy metabolism, and overall metabolic resilience. 

Biomarkers for Monitoring Methylation Balance: Homocysteine and Liver Health

Methylation is a dynamic process, and researchers and clinicians often rely on biomarkers to assess how well it’s functioning in the body.

One of the most well-known functional markers of methylation is homocysteine, an amino acid produced during methylation reactions. Elevated homocysteine levels can indicate increased methyl donor usage and potential methylation strain, suggesting that the body is working harder to maintain balance.¹⁷ In contrast, normal homocysteine levels typically indicate that methylation pathways are adequately supported by methyl donor nutrients, like folate, methionine, betaine, or choline. 

In addition to homocysteine, clinicians can also directly measure blood levels of these methyl donor nutrients to assess substrate availability. This helps to identify possible deficiencies or imbalances in the nutrients that fuel methylation reactions.

The liver is a central hub for both methylation and NAD+ metabolism, making it vital for maintaining methylation balance throughout the body. It is the site of several key methylation reactions, including those that support detoxification, lipid metabolism, and energy production. To carry out these vital processes efficiently, the liver relies heavily on methyl donors, which are crucial for sustaining normal metabolic functions and ensuring overall liver health.¹⁸ 

Given these vital functions, liver health directly affects methylation efficiency. Liver enzymes such as ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are commonly used as indirect markers of liver function.¹⁹

Elevated ALT and AST levels can signal that the liver is under strain—from inflammation, metabolic dysfunction, injury, or excessive alcohol consumption—which may interfere with the liver’s ability to carry out methylation-dependent processes, including detoxification. Similarly, liver fat accumulation, as seen in conditions like non-alcoholic fatty liver disease (NAFLD), can also signal disruptions in metabolism due to diminished methyl donor levels.²⁰

Together, these biomarkers—functional measures like homocysteine, direct measures of methyl donors, and indicators of liver health—can be used to gauge systemic methylation balance. Although no single biomarker provides a complete picture, monitoring them can provide insight into whether methylation processes are operating optimally.

DNA Methylation and Epigenetics: How Genes Are Regulated

One of the most important roles of methylation occurs at the genetic level—our DNA. DNA methylation refers to the addition of a methyl group directly onto specific sites in the DNA sequence.²¹ This is called a “chemical tag,” and it does not change the underlying DNA, but it can influence whether a gene is active (“turned on”) or silenced (“turned off”), essentially guiding how cells function and respond to the environment.

DNA methylation guides cellular identity and tissue differentiation—ensuring that a skin cell becomes skin, a blood cell behaves like a blood cell, and a neuron acts like a neuron. Without proper DNA methylation patterns, cells can lose their identity or function improperly.

DNA methylation is part of a broader field called epigenetics, which studies how factors beyond the DNA sequence itself can influence gene activity.²² Lifestyle, nutritional status, stress, and environmental exposures can all shape epigenetic patterns, implying that identical DNA sequences can produce different outcomes depending on these factors. For example, two people with the same genetic blueprint (like identical twins) can experience differences in disease risk, metabolic health, or aging due to differences in diet, lifestyle, or stress.²³ 

It’s important to note that while your DNA sequence is fixed, epigenetic marks are dynamic, adaptable, and reversible. DNA methylation can change throughout life in response to diet, exercise, toxin exposure, or age, offering flexibility in gene regulation. This highlights why diet and lifestyle matter: they can influence which genes are expressed and shape long-term health outcomes, including metabolic function, disease risk, and biological aging.²⁴

Epigenetic Aging and the Horvath Clock: Understanding DNA Methylation Patterns

Our chronological age—the number of years we’ve been alive—doesn’t always match up with our biological age, which reflects how quickly cells and tissues are aging.²⁵ While chronological age is straightforward, biological age can vary significantly between individuals. One of the best tools for estimating biological age is the Horvath epigenetic clock, developed by Dr. Steve Horvath, a pioneering researcher in epigenetic aging.²⁶ This “clock” uses DNA methylation patterns to predict our true biological age on a molecular level.

The Horvath clock is unique because it provides a cross-tissue measurement of biological age, meaning it can detect aging across a wide range of human tissues and cell types, including the liver, brain, lung, skin, and saliva. This broad applicability makes it an invaluable tool for understanding how aging affects the body as a whole, not just individual organs.

A recent meta-analysis, analyzing over 15,000 methylomes across 17 human tissues, has significantly expanded our understanding of how aging affects the epigenome.²⁷ The analysis revealed that aging induces both tissue-specific and shared epigenetic changes. Some methylation patterns were consistent across multiple tissues, suggesting systemic aging processes, while others were more localized to specific tissues, reflecting organ-specific aging mechanisms. 

It revealed that highly active tissues like the brain, liver, muscle, lung, and skin showed many age-related DNA changes. This suggests these tissues either experience more epigenetic changes with age or are more vulnerable to aging. On the other hand, tissues like the kidney, stomach, prostate, and rectum showed fewer detectable changes, possibly due to either a more stable epigenetic landscape or limited sample availability.

One key finding from the study is that aging-related methylation changes are not purely random. While some variability in methylation increased with age, many changes followed specific, directional patterns. For example, a common trend was the increase in methylation in regions that were once more "open" and active in younger individuals. This suggests that as we age, there is a gradual tightening of gene regulation—often referred to as epigenetic silencing—which may reduce cellular flexibility and resilience.

While many of the age-related methylation networks examined across tissues revealed fragile and pro-degenerative pathways that became less responsive with age, NAD+ biosynthesis, particularly through the NR salvage pathway, emerged as a notable exception. Unlike most pathways that become disrupted with age, this pathway remained unusually stable and resistant to age-related disruption, offering a rare opportunity for safe intervention.

This discovery has important implications. Since NAD+ metabolism shows resilience to aging, supporting it with compounds like NR could help keep cells energized, balanced, and resilient—without disrupting methylation.

Overall, although age-related methylation changes tend to weaken more fragile networks, NAD+ metabolism stands out as a stabilizing system. Supporting NAD+ metabolism through NR supplementation or other strategies may help slow the progression of cellular aging and promote long-term health.

B3 Vitamins and Methylation: Clinical Insights

Vitamins in the B3 family—including niacin, nicotinamide, and nicotinamide riboside (NR)—are key contributors to NAD+ metabolism, and this metabolism intersects with methylation.²⁸

When B3 vitamins are processed in the body, methylation reactions are required to clear them, producing methylated metabolites that can be detected in the blood and urine.²⁸ This biological process has raised questions about whether high-dose B3 supplementation (such as niacin or NR) could thereby deplete methyl donors. 

While all B3 vitamins contribute to NAD+ metabolism, they do not have identical effects on the body, especially at high doses. Historically, some forms—particularly niacin and nicotinamide—have been linked to liver stress or methylation strain:

  •  A 1991 case report showed that high-dose niacin was associated with rare instances of liver dysfunction or failure.²⁹
  • In a 2018 clinical study, men with dyslipidemia who took 2,000 mg of niacin daily for 8 weeks experienced increased homocysteine levels.⁶
  • A 2013 study showed that 1,500 mg of niacin per day for 12 weeks in sickle cell anemia patients led to elevated liver enzymes (ALT and AST).³⁰

While these studies provide valuable insight, it’s important to note that they involved smaller sample sizes and only involved specific populations, so the results may not be generalizable to everyone. 

Subsequent research comparing niacin and nicotinamide revealed further differences. A study from 2017 comparing niacin and nicotinamide in healthy adults showed distinct effects: nicotinamide raised homocysteine more than niacin, and both slightly reduced plasma betaine, with nicotinamide having a larger effect.³¹ These findings highlight that not all B3 vitamins behave the same way, even though they share the same vitamin classification.

In contrast to niacin and nicotinamide, clinical studies of NR—including doses up to 3,000 mg per day³²—have shown no adverse effects³³ on methylation markers, homocysteine, or liver enzymes, even in people with common MTHFR gene variants.³⁴

Some of the key findings from these studies include:

Taken together, these studies highlight that NR supports NAD+ metabolism without affecting methylation or depleting methyl donors, even in sensitive populations that have been studied.

So, what makes NR different? NR’s molecular structure and metabolism result in lower methylation demand compared with niacin or nicotinamide. While NR does increase methylated nicotinamide (MeNAM) in the liver, blood, and urine, the body’s redundant methylation systems maintain overall methyl donor balance.⁴⁰ This means that methylation remains stable, even with high-dose NR.

Some practitioners recommend taking trimethylglycine (TMG; also known as betaine)⁴¹ alongside NR as a methyl donor “insurance policy,” particularly for people with persistently elevated homocysteine or certain genetic or metabolic conditions. However, there is no clinical evidence to suggest that NR supplementation alone disrupts methylation, even in individuals with MTHFR mutations.

Overall, not all B3 vitamins are interchangeable. Unlike niacin or nicotinamide, current studies suggest NR supports NAD+ levels with minimal to no impact on methylation markers. This aligns with the resilient NR salvage pathway identified in the recent meta-analysis of aging methylation patterns,²⁷ reinforcing that NR is a safe and effective NAD+ precursor even in the context of methylation concerns.

Conclusion: Integrating Methylation, NAD+, and NR

Methylation is a foundational regulatory system that influences gene expression, energy metabolism, detoxification, and overall cellular health. Maintaining the right balance of methylation is critical, and this balance is shaped by methyl donors, dietary intake, and genetic factors like MTHFR variants. Disruptions can occur from nutrient deficiencies, environmental stressors, infection, and more, potentially impacting long-term cellular health. 

NAD+ metabolism intersects closely with methylation, and the NR salvage pathway has emerged as a particularly resilient and therapeutically relevant network in aging and longevity. While NAD+ levels naturally decline with age, the pathway itself remains stable and responsive. Clinical studies show that NR supplementation safely boosts NAD+ without adversely affecting methylation, homocysteine, or liver function, even in sensitive populations.

Notably, not all B3 vitamins behave the same. High-dose niacin and nicotinamide can stress methylation pathways, while NR supports NAD+ while preserving methylation balance. Supplementing with trimethylglycine (TMG) alongside NR is not harmful, but it is generally unnecessary, except in specific clinical situations such as persistently elevated homocysteine.

Understanding how methylation and NAD+ pathways work together allows for evidence-based strategies to support cellular health, resilience, and metabolic balance. Approaches like NR supplementation can offer a safe, targeted approach to support NAD+ metabolism while helping to preserve methylation integrity—providing a practical tool for healthy aging and long-term cellular function.

References

  1. Barres, R., & Zierath, J. R. (2011). DNA methylation in metabolic disorders. The American Journal of Clinical Nutrition, 93(4), S897–S900. https://doi.org/10.3945/ajcn.110.001933
  2. Stols-Gonçalves, D., Meijnikman, A. S., Tristão, L. S., Santos, C. L. dos, Denswil, N. P., Verheij, J., Bernardo, W. M., & Nieuwdorp, M. (2024). Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease: Liver DNA Methylation Analysis—A Systematic Review. Cells, 13(22), 1893. https://doi.org/10.3390/cells13221893
  3. Menezo, Y., Clement, P., Clement, A., & Elder, K. (2020). Methylation: An Ineluctable Biochemical and Physiological Process Essential to the Transmission of Life. International Journal of Molecular Sciences, 21(23), 9311. https://doi.org/10.3390/ijms21239311
  4. Jin, Z., & Liu, Y. (2018). DNA methylation in human diseases. Genes & Diseases, 5(1), 1–8. https://doi.org/10.1016/j.gendis.2018.01.002
  5. Friso, S., & Choi, S.-W. (2002). Gene-Nutrient Interactions and DNA Methylation. The Journal of Nutrition, 132(8), 2382S-2387S. https://doi.org/10.1093/jn/132.8.2382s
  6. Adiels, M., Chapman, M. J., Robillard, P., Krempf, M., Laville, M., Borén, J., & Group, N. S. (2018). Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis. Journal of Clinical Lipidology, 12(3), 810-821.e1. https://doi.org/10.1016/j.jacl.2018.03.083
  7. Bekdash, R. A. (2023). Methyl Donors, Epigenetic Alterations, and Brain Health: Understanding the Connection. International Journal of Molecular Sciences, 24(3), 2346. https://doi.org/10.3390/ijms24032346
  8. Anderson, O. S., Sant, K. E., & Dolinoy, D. C. (2012). Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. The Journal of Nutritional Biochemistry, 23(8), 853–859. https://doi.org/10.1016/j.jnutbio.2012.03.003
  9. Meng, H., Cao, Y., Qin, J., Song, X., Zhang, Q., Shi, Y., & Cao, L. (2015). DNA Methylation, Its Mediators and Genome Integrity. International Journal of Biological Sciences, 11(5), 604–617. https://doi.org/10.7150/ijbs.11218
  10. Araszkiewicz, A. F., Jańczak, K., Wójcik, P., Białecki, B., Kubiak, S., Szczechowski, M., & Januszkiewicz-Lewandowska, D. (2025). MTHFR Gene Polymorphisms: A Single Gene with Wide-Ranging Clinical Implications—A Review. Genes, 16(4), 441. https://doi.org/10.3390/genes16040441
  11. Mu, S., Wang, W., Liu, Q., Ke, N., Li, H., Sun, F., Zhang, J., & Zhu, Z. (2024). Autoimmune disease: a view of epigenetics and therapeutic targeting. Frontiers in Immunology, 15, 1482728. https://doi.org/10.3389/fimmu.2024.1482728
  12. Zhang, N., Tian, X., Yan, T., Wang, H., Zhang, D., Lin, C., Liu, Q., & Jiang, S. (2023). Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease. Frontiers in Immunology, 14, 1148722. https://doi.org/10.3389/fimmu.2023.1148722
  13. Ma, Y., Wang, X., & Li, X. (2025). The emerging role of DNA methylation in the pathogenicity of bacterial pathogens. Journal of Bacteriology, 207(8), e00108-25. https://doi.org/10.1128/jb.00108-25
  14. Wielscher, M., Mandaviya, P. R., Kuehnel, B., Joehanes, R., Mustafa, R., Robinson, O., Zhang, Y., Bodinier, B., Walton, E., Mishra, P. P., Schlosser, P., Wilson, R., Tsai, P.-C., Palaniswamy, S., Marioni, R. E., Fiorito, G., Cugliari, G., Karhunen, V., Ghanbari, M., … Järvelin, M.-R. (2022). DNA methylation signature of chronic low-grade inflammation and its role in cardio-respiratory diseases. Nature Communications, 13(1), 2408. https://doi.org/10.1038/s41467-022-29792-6
  15. McKee, S. E., & Reyes, T. M. (2018). Effect of supplementation with methyl-donor nutrients on neurodevelopment and cognition: considerations for future research. Nutrition Reviews, 76(7), 497–511. https://doi.org/10.1093/nutrit/nuy007
  16. Sambamoorthy, G., & Raman, K. (2018). Understanding the evolution of functional redundancy in metabolic networks. Bioinformatics, 34(17), i981–i987. https://doi.org/10.1093/bioinformatics/bty604
  17. Mandaviya, P. R., Stolk, L., & Heil, S. G. (2014). Homocysteine and DNA methylation: A review of animal and human literature. Molecular Genetics and Metabolism, 113(4), 243–252. https://doi.org/10.1016/j.ymgme.2014.10.006
  18. Obeid, R. (2013). The Metabolic Burden of Methyl Donor Deficiency with Focus on the Betaine Homocysteine Methyltransferase Pathway. Nutrients, 5(9), 3481–3495. https://doi.org/10.3390/nu5093481
  19. Kalas, M. A., Chavez, L., Leon, M., Taweesedt, P. T., & Surani, S. (2021). Abnormal liver enzymes: A review for clinicians. World Journal of Hepatology, 13(11), 1688–1698. https://doi.org/10.4254/wjh.v13.i11.1688
  20. Hyun, J., & Jung, Y. (2020). DNA Methylation in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 21(21), 8138. https://doi.org/10.3390/ijms21218138
  21. Moore, L. D., Le, T., & Fan, G. (2013). DNA Methylation and Its Basic Function. Neuropsychopharmacology, 38(1), 23–38. https://doi.org/10.1038/npp.2012.112
  22. Jain, R., & Epstein, J. A. (2024). Congenital Heart Diseases: The Broken Heart, Clinical Features, Human Genetics and Molecular Pathways. Advances in Experimental Medicine and Biology, 1441, 341–364. https://doi.org/10.1007/978-3-031-44087-8_18
  23. Bell, J. T., & Spector, T. D. (2011). A twin approach to unraveling epigenetics. Trends in Genetics, 27(3), 116–125. https://doi.org/10.1016/j.tig.2010.12.005
  24. Unnikrishnan, A., Freeman, W. M., Jackson, J., Wren, J. D., Porter, H., & Richardson, A. (2019). The role of DNA methylation in epigenetics of aging. Pharmacology & Therapeutics, 195, 172–185. https://doi.org/10.1016/j.pharmthera.2018.11.001
  25. Liu, W., You, J., Ge, Y., Wu, B., Zhang, Y., Chen, S., Zhang, Y., Huang, S., Ma, L., Feng, J., Cheng, W., & Yu, J. (2023). Association of biological age with health outcomes and its modifiable factors. Aging Cell, 22(12), e13995. https://doi.org/10.1111/acel.13995
  26. Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Hou, L., Baccarelli, A. A., Stewart, J. D., Li, Y., Whitsel, E. A., Wilson, J. G., Reiner, A. P., Aviv, A., Lohman, K., Liu, Y., Ferrucci, L., & Horvath, S. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY), 10(4), 573–591. https://doi.org/10.18632/aging.101414
  27. Jacques, M., Seale, K., Voisin, S., Lysenko, A., Grolaux, R., Jones-Freeman, B., Lamon, S., Levinger, I., Bauer, C., Sharples, A. P., Heikkinen, A., Sillanpaa, E., Ollikainen, M., Smith, C., Broatch, J. R., Zarekookandeh, N., Gillberg, L., Blom, I., Poganik, J., … Eynon, N. (2025). DNA Methylation Ageing Atlas Across 17 Human Tissues. bioRxiv, 2025.07.21.665830. https://doi.org/10.1101/2025.07.21.665830
  28. Makarov, M. V., Trammell, S. A. J., & Migaud, M. E. (2018). The chemistry of the vitamin B3 metabolome. Biochemical Society Transactions, 47(1), 131–147. https://doi.org/10.1042/bst20180420
  29. Fischer, D. J., Knight, L. L., & Vestal, R. E. (1991). Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. The Western Journal of Medicine, 155(4), 410–412.
  30. Scoffone, H. M., Krajewski, M., Zorca, S., Bereal-Williams, C., Littel, P., Seamon, C., Mendelsohn, L., Footman, E., Abi-Jaoudeh, N., Sachdev, V., Machado, R. F., Cuttica, M., Shamburek, R., Cannon, R. O., Remaley, A., Minniti, C. P., & Kato, G. J. (2013). Effect of Extended-Release Niacin on Serum Lipids and on Endothelial Function in Adults With Sickle Cell Anemia and Low High-Density Lipoprotein Cholesterol Levels. The American Journal of Cardiology, 112(9), 1499–1504. https://doi.org/10.1016/j.amjcard.2013.06.035
  31. Sun, W.-P., Zhai, M.-Z., Li, D., Zhou, Y., Chen, N.-N., Guo, M., & Zhou, S.-S. (2017). Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clinical Nutrition, 36(4), 1136–1142. https://doi.org/10.1016/j.clnu.2016.07.016
  32. Berven, H., Kverneng, S., Sheard, E., Søgnen, M., Geijerstam, S. A. A., Haugarvoll, K., Skeie, G.-O., Dölle, C., & Tzoulis, C. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nature Communications, 14(1), 7793. https://doi.org/10.1038/s41467-023-43514-6
  33. Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286. https://doi.org/10.1038/s41467-018-03421-7
  34. Gaare, J. J., Dölle, C., Brakedal, B., Brügger, K., Haugarvoll, K., Nido, G. S., & Tzoulis, C. (2023). Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson’s disease. iScience, 26(3), 106278. https://doi.org/10.1016/j.isci.2023.106278
  35. Dollerup, O. L., Christensen, B., Svart, M., Schmidt, M. S., Sulek, K., Ringgaard, S., Stødkilde-Jørgensen, H., Møller, N., Brenner, C., Treebak, J. T., & Jessen, N. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. The American Journal of Clinical Nutrition, 108(2), 343–353. https://doi.org/10.1093/ajcn/nqy132
  36. Elhassan, Y. S., Kluckova, K., Fletcher, R. S., Schmidt, M. S., Garten, A., Doig, C. L., Cartwright, D. M., Oakey, L., Burley, C. V., Jenkinson, N., Wilson, M., Lucas, S. J. E., Akerman, I., Seabright, A., Lai, Y.-C., Tennant, D. A., Nightingale, P., Wallis, G. A., Manolopoulos, K. N., … Lavery, G. G. (2019). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports, 28(7), 1717-1728.e6. https://doi.org/10.1016/j.celrep.2019.07.043
  37. Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports, 9(1), 9772. https://doi.org/10.1038/s41598-019-46120-z
  38. Gaare, J. J., Dölle, C., Brakedal, B., Brügger, K., Haugarvoll, K., Nido, G. S., & Tzoulis, C. (2023). Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson’s disease. iScience, 26(3), 106278. https://doi.org/10.1016/j.isci.2023.106278
  39. Berven, H., Kverneng, S., Sheard, E., Søgnen, M., Geijerstam, S. A. A., Haugarvoll, K., Skeie, G.-O., Dölle, C., & Tzoulis, C. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nature Communications, 14(1), 7793. https://doi.org/10.1038/s41467-023-43514-6
  40. Pissios, P. (2017). Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology & Metabolism, 28(5), 340–353. https://doi.org/10.1016/j.tem.2017.02.004
  41. Arumugam, M. K., Paal, M. C., Donohue, T. M., Ganesan, M., Osna, N. A., & Kharbanda, K. K. (2021). Beneficial Effects of Betaine: A Comprehensive Review. Biology, 10(6), 456. https://doi.org/10.3390/biology10060456